Database study reveals clinical usage of HIF-PH inhibitors and ESAs for anemia management in CKD patients, highlighting emerging trends.
Background Hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors were introduced for the treatment of anemia in chronic kidney disease (CKD) in Japan in 2020; however, data on their use in clinical practice remain limited.
No takes yet. Share an insight, caveat, or question.
Ueta et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: